ATE508745T1 - Kombination umfassend mindestens eine aminosäure und einen pkr-inhibitor zur verwendung in der behandlung von muskelschwund - Google Patents

Kombination umfassend mindestens eine aminosäure und einen pkr-inhibitor zur verwendung in der behandlung von muskelschwund

Info

Publication number
ATE508745T1
ATE508745T1 AT06838457T AT06838457T ATE508745T1 AT E508745 T1 ATE508745 T1 AT E508745T1 AT 06838457 T AT06838457 T AT 06838457T AT 06838457 T AT06838457 T AT 06838457T AT E508745 T1 ATE508745 T1 AT E508745T1
Authority
AT
Austria
Prior art keywords
bcaa
amino acid
combination
treatment
muscle wasting
Prior art date
Application number
AT06838457T
Other languages
English (en)
Inventor
Michael Tisdale
Norman Alan Greenberg
Helen Eley
Kevin Burke Miller
Original Assignee
Novartis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Pharma Gmbh filed Critical Novartis Pharma Gmbh
Application granted granted Critical
Publication of ATE508745T1 publication Critical patent/ATE508745T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Addiction (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Gastroenterology & Hepatology (AREA)
AT06838457T 2005-11-30 2006-11-28 Kombination umfassend mindestens eine aminosäure und einen pkr-inhibitor zur verwendung in der behandlung von muskelschwund ATE508745T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US74109205P 2005-11-30 2005-11-30
US78094106P 2006-03-09 2006-03-09
PCT/US2006/045497 WO2007064618A1 (en) 2005-11-30 2006-11-28 Methods for the treatment of muscle loss

Publications (1)

Publication Number Publication Date
ATE508745T1 true ATE508745T1 (de) 2011-05-15

Family

ID=37806127

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06838457T ATE508745T1 (de) 2005-11-30 2006-11-28 Kombination umfassend mindestens eine aminosäure und einen pkr-inhibitor zur verwendung in der behandlung von muskelschwund

Country Status (18)

Country Link
US (1) US8329646B2 (de)
EP (1) EP1957061B1 (de)
JP (1) JP5260303B2 (de)
CN (1) CN101316582A (de)
AT (1) ATE508745T1 (de)
AU (1) AU2006320670B8 (de)
BR (1) BRPI0619179A2 (de)
CA (1) CA2631647A1 (de)
DK (1) DK1957061T3 (de)
ES (1) ES2363442T3 (de)
HK (1) HK1118455A1 (de)
IL (1) IL191374A0 (de)
MY (1) MY147489A (de)
PT (1) PT1957061E (de)
RU (1) RU2414897C2 (de)
SG (1) SG163600A1 (de)
WO (1) WO2007064618A1 (de)
ZA (1) ZA200805657B (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2340725A1 (de) * 2005-10-28 2011-07-06 Nestec S.A. Methoden zur verwendung von verzweigten aminosäuren
DE102007016715A1 (de) * 2007-04-04 2008-10-09 Evonik Degussa Gmbh Nahrungsergänzungsmittel enthaltend alpha-Ketosäuren
CA2706656A1 (en) * 2007-11-26 2009-06-04 Nestec S.A. Compositions and methods for inhibiting the activation of dsrna-dependent protein kinase and tumor growth inhibition
WO2009099628A2 (en) 2008-02-07 2009-08-13 Nestec S.A. Compositions and methods for influencing recovery from strenuous physical activity
EP2274002B1 (de) * 2008-03-26 2014-12-03 Glanbia Nutritionals (Ireland) Limited Leucinreiche peptid-zusammensetzungen und gewinnungsverfahren
US20130236447A1 (en) * 2008-12-23 2013-09-12 Carmel-Haifa University Economic Corp., Ltd. Cognitive function
JP2013519869A (ja) 2010-02-10 2013-05-30 ノバルティス アーゲー 筋肉成長のための方法および化合物
EA201300947A1 (ru) * 2011-02-25 2014-02-28 Мерк Патент Гмбх Композиция для повышения устойчивости суставов и/или позной устойчивости
RU2454227C1 (ru) * 2011-04-05 2012-06-27 Федеральное государственное учреждение "Российский научный центр "Восстановительная травматология и ортопедия" имени академика Г.А. Илизарова" Министерства здравоохранения и социального развития Российской Федерации Композиция для восстановления скелетных мышц и кости при скелетной травме
CN103889411B (zh) 2011-07-15 2018-03-16 纽斯尔特科学公司 用于调节代谢途径的组合物和方法
KR20140121475A (ko) * 2012-02-06 2014-10-15 아지노모토 가부시키가이샤 특발성 염증성 근질환의 예방 또는 치료제
AU2013240184B2 (en) 2012-03-26 2017-05-25 Axcella Health Inc. Nutritive fragments, proteins and methods
EP2831102A4 (de) 2012-03-26 2015-12-02 Pronutria Inc Nährmittelfragmente, proteine damit und verfahren
AU2013240183B2 (en) 2012-03-26 2016-10-20 Axcella Health Inc. Charged nutritive proteins and methods
WO2013148328A1 (en) 2012-03-26 2013-10-03 Pronutria, Inc. Nutritive proteins and methods
JP5477413B2 (ja) * 2012-04-24 2014-04-23 味の素株式会社 分岐鎖アミノ酸の心不全適応
MX2015006023A (es) 2012-11-13 2016-03-31 Nusirt Sciences Inc Composiciones y metodos para incrementar el metabolismo energetico.
RU2517576C1 (ru) * 2013-03-06 2014-05-27 Федеральное государственное бюджетное учреждение науки Государственный научный центр Российской Федерации-Институт медико-биологических проблем Российской академии наук (ГНЦ РФ-ИМБП РАН) Средство для профилактики и снижения деструкции белков скелетных мышц при их атрофии, вызванной гипокинезией и/или гравитационной разгрузкой
EP2986113B1 (de) * 2013-04-16 2020-08-26 The Children's Hospital of Philadelphia Zusammensetzungen und verfahren zur behandlung von gehirnverletzungen
BR112015027563A2 (pt) * 2013-05-01 2017-07-25 Abbott Lab métodos para melhorar a regeneração do músculo envelhecido
CN103416760B (zh) * 2013-08-28 2014-09-10 山东卫康生物医药科技有限公司 治疗和预防肌肉衰减综合症的五谷杂粮全营养配方食品
CN107223020A (zh) 2013-09-25 2017-09-29 胺细拉健康公司 用于预防和治疗糖尿病和肥胖症的组合物和制剂及其产生和用于葡萄糖和卡路里控制的方法
KR101668074B1 (ko) * 2015-02-12 2016-10-21 전북대학교산학협력단 Ｐｋｒ 저해제를 유효성분으로 포함하는 기관지 천식의 예방 또는 치료용 조성물
CN105747214A (zh) * 2016-02-26 2016-07-13 四川安益生物科技有限公司 一种支链氨基酸组合物
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
WO2019036471A1 (en) 2017-08-14 2019-02-21 Axcella Health Inc. AMINO ACIDS BRANCHED FOR THE TREATMENT OF LIVER DISEASE
CN107440126A (zh) * 2017-09-08 2017-12-08 天津活力达生物科技有限公司 一种缓解运动疲劳的蛋白粉及其制备方法
BR112020021283A2 (pt) 2018-04-18 2021-01-26 Worlds Greatest Ingredients, LP composição para aumentar massa muscular, e, métodos para prevenir ou tratar atrofia muscular e para aumentar massa muscular e/ou força muscular.
RU2686086C1 (ru) * 2018-05-17 2019-04-24 федеральное государственное бюджетное образовательное учреждение высшего образования "Первый Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова" Министерства здравоохранения Российской Федерации Способ коррекции пресаркопении или саркопении у пациента с адекватным потреблением основных нутриентов, получающего лечение программным гемодиализом
AR115585A1 (es) 2018-06-20 2021-02-03 Axcella Health Inc Composiciones y métodos para el tratamiento de la infiltración de grasa en músculo
BR112021022752A2 (pt) * 2019-06-20 2022-03-22 Nestle Sa Composições e métodos para potencializar o efeito músculo-esquelético de um ou mais aminoácidos anabólicos
IT201900010437A1 (it) * 2019-06-28 2020-12-28 Dompe Farm Spa Composizione per il trattamento del deperimento muscolare

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4491589A (en) * 1982-05-17 1985-01-01 The Trustees Of Columbia University In The City Of New York Amino acid solutions for parenteral nutrition and methods of formulation and use
US4677121A (en) * 1985-01-22 1987-06-30 The Johns Hopkins University Method of inhibiting muscle protein degradation
US4780475A (en) * 1986-02-03 1988-10-25 Cerra Frank B Preparation for the prevention of catabolism
US5087472A (en) * 1990-01-30 1992-02-11 Iowa State University Research Foundation, Inc. Feed compositions for domestics animals containing hydroxymethylbutyrate
JPH03264525A (ja) * 1990-03-14 1991-11-25 Otsuka Pharmaceut Factory Inc アミノ酸輸液
US6608109B2 (en) * 1991-11-20 2003-08-19 Allen Ann De Wees Composition comprising L-arginine as a muscle growth stimulant and use thereof
US6077828A (en) * 1996-04-25 2000-06-20 Abbott Laboratories Method for the prevention and treatment of cachexia and anorexia
US5716926A (en) * 1996-07-26 1998-02-10 Paxton K. Beale Composition of pyruvate and protein and method for increasing protein concentration in a mammal
DE19757250A1 (de) * 1997-12-22 1999-07-01 Forssmann Wolf Georg Prof Dr Insulin-like growth factor binding protein und seine Verwendung
US5817695A (en) * 1997-12-24 1998-10-06 Pellico; Michael A. Nutritional product with high fat, low carbohydrate and amino acid imbalance
US6031000A (en) * 1998-06-23 2000-02-29 Iowa State University Research Foundation, Inc. Composition comprising β-hydroxy-β-methylbutyric acid and at least one amino acid and methods of use
US6184226B1 (en) * 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
CN1261098C (zh) * 1998-08-28 2006-06-28 西奥斯股份有限公司 p38－α激酶的抑制剂
US6051236A (en) * 1998-11-12 2000-04-18 Pacifichealth Laboratories, Inc. Composition for optimizing muscle performance during exercise
CZ20022927A3 (cs) * 2000-02-01 2003-06-18 Muscletech Research And Development Inc. Doplňky stravy založené na alfa-lipoové kyselině pro zvýšení čisté svalové hmoty a síly
EP1364949A4 (de) * 2001-02-02 2005-11-23 Takeda Pharmaceutical Jnk inhibitor
US6503506B1 (en) * 2001-08-10 2003-01-07 Millenium Biotechnologies, Inc. Nutrient therapy for immuno-compromised patients
FR2833012B1 (fr) * 2001-12-04 2004-01-30 Centre Nat Rech Scient Peptides agonistes de l'hormone de croissance et leurs applications
US7744930B2 (en) * 2002-11-22 2010-06-29 Shaklee Corporation Compositions, methods and kits for enhancing weight loss while inhibiting loss of lean body mass
US8703209B2 (en) 2003-06-17 2014-04-22 Edward Larry McCleary Composition and method for modulating hydrogen ion physiology
US7820702B2 (en) 2004-02-04 2010-10-26 Bristol-Myers Squibb Company Sulfonylpyrrolidine modulators of androgen receptor function and method
EP1781687A1 (de) * 2004-08-25 2007-05-09 Santhera Pharmaceuticals (Schweiz) AG Alpha-keto-carbonyl-calpainhemmer
EP2340725A1 (de) * 2005-10-28 2011-07-06 Nestec S.A. Methoden zur verwendung von verzweigten aminosäuren
US7790688B2 (en) * 2008-01-11 2010-09-07 Healthspan Solutions, Llc Compositions and methods for increasing muscle mass, strength, and functional performance in the elderly

Also Published As

Publication number Publication date
CA2631647A1 (en) 2007-06-07
BRPI0619179A2 (pt) 2011-09-13
ZA200805657B (en) 2009-12-30
RU2008126294A (ru) 2010-01-10
EP1957061A1 (de) 2008-08-20
WO2007064618A1 (en) 2007-06-07
SG163600A1 (en) 2010-08-30
JP5260303B2 (ja) 2013-08-14
AU2006320670B8 (en) 2011-04-07
ES2363442T3 (es) 2011-08-04
DK1957061T3 (da) 2011-07-25
RU2414897C2 (ru) 2011-03-27
AU2006320670B2 (en) 2010-12-09
AU2006320670A1 (en) 2007-06-07
IL191374A0 (en) 2009-08-03
PT1957061E (pt) 2011-07-06
JP2009517473A (ja) 2009-04-30
US20090105123A1 (en) 2009-04-23
WO2007064618A8 (en) 2008-11-06
HK1118455A1 (en) 2009-02-13
CN101316582A (zh) 2008-12-03
EP1957061B1 (de) 2011-05-11
US8329646B2 (en) 2012-12-11
MY147489A (en) 2012-12-14

Similar Documents

Publication Publication Date Title
ATE508745T1 (de) Kombination umfassend mindestens eine aminosäure und einen pkr-inhibitor zur verwendung in der behandlung von muskelschwund
ATE449602T1 (de) Arzneimittel mit dobesilat-calcium zur behandlung und prophylaxe von sehnenerkrankungen
BR0313282A (pt) Composições de inibidor seletivo de ciclooxigenase-2 e um inibidor de anidrase carbÈnica para o tratamento de neoplasia
BRPI0410972C1 (pt) método para aumentar a vida de armazenagem de uma composição farmacêutica, composição farmacêutica, e, método para tratamento de hiperglicemia
NO20082790L (no) Behandling av type 2 diabetes med en kombinasjon av DPIV inhibitor og metformin eller thiazolidindion
CO6300826A2 (es) Metodos y composiciones que utilizan polipeptidos de fusion de klotho-fgf
DE60215787D1 (de) Behandlung von typ ii diabetes mit dipeptidyl-peptidase-iv-hemmern
EA200601776A1 (ru) Метадоновые композиции местного действия и способы их применения
DE602004012745D1 (de) Synergistische zusammensetzung zur behandlung von diabetes mellitus
AR049955A1 (es) Composiciones y metodos para el tratamiento de trastornos metabolicos
ATE474568T1 (de) Synergistische kombination von (-) -gossypol mit docetaxel oder paclitaxel zur behandlung von krebs.
DE602004031134D1 (de) Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
DE602005026276D1 (de) Myricitrin verbindungen zur behandlung von schlafstörungen
BRPI0512503A (pt) composição que compreende ácido lático e lactoferrina
UA88165C2 (en) Use of trisubstituted benzopyranones
ATE533488T1 (de) Verfahren und formulierungen zur modulierung von lyn-kinaseaktivität und behandlung assoziierter erkrankungen
DE602004016385D1 (de) Zusammensetzungen mit pantothensäure oder derivaten davon und ihre verwendung zur stimulierung des appetits
ATE468849T1 (de) Idebenon zur behandlung von muskeldystrophien
ATE397453T1 (de) Zusammensetzung zur behandlung und/oder vorbeugung von insulinresistenz
NO20051159L (no) Preparater og fremgangsmater for behandling av sykdommer som viser feilsammensetting av aggregering av protein
ATE358992T1 (de) Enteralpräparat zur vorbeugung gegen bzw. behandlung von sepsis
ATE546159T1 (de) Neue arzneimittelkombinationen zur behandlung von atemwegserkrankungen enthaltend langwirksame beta-2-agonisten und wenigstens einen weiteren wirkstoff
ATE406171T1 (de) Aplidine zur behandlung von multiplem myelom
DE602006016413D1 (de) Kim-1-antikörper zur behandlung von th2-vermittelten erkrankungen
TW200603792A (en) Monotherapy for the treatment of psoriasis with cyclooxygenase-2 selective inhibitors

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1957061

Country of ref document: EP